Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of brexpiprazole for irritability associated with autism spectrum disorder in children and adolescents
2019-000723-40Phase 3
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Rexulti with Placebo (2 arms). Primary endpoint: Mean change from baseline to Week 8 in Aberrant Behavior Checklist-Irritability subscale score.
02
Drugs
brexpiprazole
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2019-000723-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000723-40.